Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Russi A, Svegliati E, Baldo P, Orzetti S, Enrico F, Foglio F, Pinnavaia D, Ladisa V, Lauria Pantano C, Lerose R, Nardulli P, Ferraiuolo S, Maiolino P, De Stasio I, Gradellini F, Gasbarro AR, Santeramo R, Carrucciu G, Provasi R, Cirino M, Cappelletto PC, Fonzi E, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: coppola m. Cancers (Basel). 2024 May 8;16(10):1802. doi: 10.3390/cancers16101802. Cancers (Basel). 2024. PMID: 38791882 Free PMC article.
A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Baldo P, Orzetti S, Enrico F, Ladisa V, Lerose R, Nardulli P, Maiolino P, Gradellini F, Gasbarro AR, Carrucciu G, Provasi R, Cappelletto PC, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: coppola m. Front Oncol. 2024 Mar 27;14:1351995. doi: 10.3389/fonc.2024.1351995. eCollection 2024. Front Oncol. 2024. PMID: 38601759 Free PMC article.
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
Bonanno L, Lorenzi M, Massa D, De Nuzzo M, Angerilli V, Zingone F, Barberio B, Russi A, Girardi F, Ferro A, Dal Maso A, Frega S, Pasello G, Dei Tos AP, Coppola M, Fassan M, Savarino EV, Guarneri V. Bonanno L, et al. Among authors: coppola m. Oncologist. 2024 Jan 5;29(1):e118-e130. doi: 10.1093/oncolo/oyad238. Oncologist. 2024. PMID: 37603442 Free PMC article.
Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.
Caccese M, Desideri I, Padovan M, Bruno F, Cerretti G, Fiorentino A, Denaro L, Chioffi F, Della Puppa A, Maccari M, Cavallin F, Coppola M, Pittaro A, Rudà R, Livi L, Lombardi G. Caccese M, et al. Among authors: coppola m. J Neurooncol. 2023 Jun;163(2):377-383. doi: 10.1007/s11060-023-04356-w. Epub 2023 Jun 1. J Neurooncol. 2023. PMID: 37264256 Free PMC article.
Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations.
Carpanese D, Rossi V, Di Paolo V, Quintieri L, Penna A, Zuccolotto G, Sebellin J, Saran C, Pipitone F, Miolo G, De Diana E, Realdon N, Rigamonti N, Di Sarra F, Coppola M, Rosato A. Carpanese D, et al. Among authors: coppola m. Int J Pharm. 2024 Jan 5;649:123643. doi: 10.1016/j.ijpharm.2023.123643. Epub 2023 Nov 30. Int J Pharm. 2024. PMID: 38040395 Free article.
515 results